Want to see AU:AGN full AI Analyst Report?
Top Page
Argenica Therapeutics Ltd
(Sydney:AGN)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.10
▼(-49.50% Downside)
Action:Reiterated
Date:09/24/26
The score is driven primarily by weak financial performance (zero revenue in 2026, ongoing operating losses, and persistent cash burn) despite the benefit of a debt-free balance sheet. Technical indicators add further downside risk with the price below all key moving averages and bearish momentum. Valuation provides limited support because losses make the negative P/E less informative and no dividend yield is available.
Positive Factors
Debt-free balance sheet
Zero debt reduces leverage and refinancing risk while preserving financial flexibility. Although losses remain significant, the absence of borrowing costs gives management more room to direct available capital toward development activities and limits the balance-sheet damage that rising interest obligations could create.
Negative Factors
Revenue collapse
The sharp reversal to zero revenue indicates that recent commercial momentum has not been sustained. Without recurring revenue, the company remains dependent on development progress and external funding, making it harder to cover operating costs, support research programs, or establish a predictable business model.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Zero debt reduces leverage and refinancing risk while preserving financial flexibility. Although losses remain significant, the absence of borrowing costs gives management more room to direct available capital toward development activities and limits the balance-sheet damage that rising interest obligations could create.
Read all positive factors
Argenica Therapeutics Ltd (AGN) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$13.49M
Dividend YieldN/A
Average Volume (3M)58.27K
Price to Earnings (P/E)―
Beta (1Y)1.41
Revenue GrowthN/A
EPS Growth81.00%
CountryAU
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.01
Shares Outstanding128,456,710
10 Day Avg. Volume52,755
30 Day Avg. Volume58,268
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)2.09
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.07
Revenue Forecast (FY)AU$28.10M
Argenica Therapeutics Ltd Business Overview & Revenue Model
Company Description
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clin...
Argenica Therapeutics Ltd Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 3.21M | 2.60M | 1.75M | 259.10K |
| Gross Profit | 0.00 | 3.21M | 2.60M | 1.75M | 259.10K |
| EBITDA | -7.06M | 0.00 | -1.90M | -1.32M | -257.41K |
| Net Income | -1.37M | -7.17M | -5.48M | -4.82M | -4.09M |
Balance Sheet | |||||
| Total Assets | 6.52M | 11.04M | 16.38M | 9.54M | 9.04M |
| Cash, Cash Equivalents and Short-Term Investments | 6.36M | 10.56M | 15.91M | 9.34M | 8.91M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 614.55K | 3.80M | 2.43M | 1.87M | 735.91K |
| Stockholders Equity | 5.90M | 7.24M | 13.95M | 7.67M | 8.31M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -5.70M | -5.06M | -3.30M | -3.36M |
| Operating Cash Flow | -4.19M | -5.70M | -5.06M | -3.30M | -3.36M |
| Investing Cash Flow | 0.00 | 0.00 | 50.00K | -50.00K | 0.00 |
| Financing Cash Flow | -2.94K | 346.90K | 11.63M | 3.73M | 5.13M |
Argenica Therapeutics Ltd Technical Analysis
Negative
0.20
Price Trends
0.15
Negative
0.14
Negative
0.17
Negative
Market Momentum
-0.01
Positive
35.65
Neutral
-5.09
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:AGN, the sentiment is Negative. The current price of 0.2 is above the 20-day moving average (MA) of 0.12, above the 50-day MA of 0.15, and above the 200-day MA of 0.17, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 35.65 is Neutral, neither overbought nor oversold. The STOCH value of -5.09 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:AGN.
Argenica Therapeutics Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$12.36M | -1.67 | -247.44% | ― | -4.24% | 33.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | AU$5.44M | -1.02 | -52.04% | ― | 32.22% | -26.53% | |
42 Neutral | AU$30.39M | -0.34 | -118.74% | ― | 499.47% | 31.20% | |
42 Neutral | AU$13.49M | -9.91 | -29.22% | ― | ― | 81.00% | |
42 Neutral | AU$4.02M | -0.31 | -617.89% | ― | ― | 13.67% | |
40 Underperform | AU$19.26M | -5.71 | -132.20% | ― | ― | -200.00% |
* Healthcare Sector Average
AU:AGN
Argenica Therapeutics Ltd
0.11
-0.19
-64.41%
AU:CYP
Cynata Therapeutics Limited
0.01
-0.24
-95.26%
AU:1AI
Living Cell Technologies
0.01
0.00
0.00%
AU:TRP
Tissue Repair Ltd
0.09
-0.25
-73.53%
AU:CMB
Regeneus Ltd.
0.42
-0.06
-12.50%
AU:BOT
Botanix Pharmaceuticals Limited
0.01
-0.12
-91.54%
Argenica Therapeutics Ltd Corporate Events
Argenica strengthens scientific case for multi-target stroke drug xaranetide
Oct 19, 2026
Argenica Therapeutics has reported new pharmacology data showing that its lead drug candidate xaranetide inhibits several key ion channels involved in acute brain injury, including specific NMDA receptor subunits, ASIC1a and CaV2.2. The studies in...
Argenica sets 2026 AGM date and shifts to digital shareholder communications
Oct 19, 2026
Argenica Therapeutics has scheduled its 2026 Annual General Meeting for 19 November at the UWA Club in Crawley, Western Australia, with meeting materials, including the notice and annual report, available online through the company’s website...
Argenica Director Boosts Direct Shareholding in On-Market Trade
Sep 29, 2026
Argenica Therapeutics has disclosed a change in the shareholding of director Dr Jeannette Anne Joughin following an on-market purchase of ordinary shares. The transaction, conducted on 29 September 2026, involved the acquisition of 142,643 ordinar...
Argenica Sets 2026 AGM Date and Director Nomination Deadline
Sep 22, 2026
Argenica Therapeutics has scheduled its Annual General Meeting for Thursday, 19 November 2026, with full details on the venue and resolutions to be provided in a forthcoming Notice of AGM and Explanatory Memorandum to shareholders. The company has...
Argenica’s xaranetide concussion data earns international neurotrauma spotlight
Sep 14, 2026
Argenica Therapeutics reported that preclinical data from its concussion program on xaranetide (ARG-007) have been selected for an oral presentation at the 2026 International NeuroTrauma Society meeting in Colombia. The study, led by researchers a...
Argenica Files 2026 Corporate Governance Statement with ASX
Aug 26, 2026
Argenica Therapeutics Ltd has lodged its Appendix 4G and corporate governance statement for the financial year ended 30 June 2026, confirming compliance with ASX Listing Rules on governance reporting. The statement, current as of 26 August 2026, i...
Argenica Narrows Annual Loss as R&D Support Boosts Revenue
Aug 26, 2026
Argenica Therapeutics reported a 53% increase in revenue to $5.7 million for the year to 30 June 2026, driven mainly by a larger RD tax incentive rebate and higher government grant income, while narrowing its after-tax loss by 81% to $1.37 million...
Argenica Options Lapse Trims Potential Diluted Capital
Aug 13, 2026
Argenica Therapeutics has announced the cessation of 200,000 AGNAM options, which were due to expire in April 2029 with an exercise price of $0.42. The options lapsed because the conditions attached to these rights were not met or became incapable...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.